Articles
Are All Anti-tumor Necrosis Factor Antibodies the Same in Crohn’s Disease?—A Systematic Review with Commentary
Structure and Pharmacology of Tumor Necrosis Factor-α Antagonists The unique pharmacologic profiles among the three anti-TNF-α antibodies and their...
Certolizumab Pegol in Crohn’s Disease
Traditional Therapies in Crohn’s Disease Anti-inflammatory drugs and oral immunosuppressants have traditionally been the mainstay for treating...
Colonic Drug Delivery Challenges and Oppor tunities - An Overview
The overall goal for optimum therapy is to match the needs of the patient while improving the efficiency and safety of the administered drugs....
Developments in the Treatment of Inflammatory Bowel Disease
AminosalicylatesThe release of balsalazide disodium (Colazal® in the US; Colazide® in Europe; Salix Pharmaceuticals, Raleigh, North Carolina)...
Eosinophils in Inflammatory Bowel Disease
Clinical Evidence of the Diagnostic and Prognostic Values of Eosinophils in IBDAn increased number of eosinophils have been found in the gut mucosa...
Fifty Years of the World Gastroenterology Organisation
In parallel with these organizational developments, the field of gastroenterology itself has witnessed tremendous progress. Who could have envisaged...
Genetics of Inflammatory Bowel Disease
Evidence of Genetic Susceptibility in Disease Pathogenesis There are considerable epidemiological data that implicate genetic susceptibility in the...
Improving Mucosal Barrier Function A Novel Therapeutic Strategy for Crohn s Disease
The intestinal mucosal barrier is composed of not only the mucosal epithelium, but also a highly integrated immune system. Recent evidence suggests...
Optimising Biologic Therapies for Maximal Effect in Crohn s Disease
Overview of Pivotal Anti-tumour Necrosis Factor Trials Infliximab was the first and has been the most extensive anti-TNF agent evaluated in the...
Second-line Medical Therapy for Acute Severe Ulcerative Colitis – Saving Colons or Risking Lives?
It is clear that 30–40% of patients will not respond to corticosteroid therapy, and the current standard of care for these patients remains urgent...
The Effects of Treatment on Histology in Inflammatory Bowel Disease
Changes in IBD Histology with Time and Treatment The traditional description of UC is that of a disease affecting the rectum and extending to a...
The Most Significant Advances in the Management of Crohn’s Disease
Biological Agents Infliximab (a chimaeric humanised anti-tumour necrosis factor [TNF]-α antibody) was the first TNF-α inhibitor approved for the...
The Role of Inflammation in the Course of Crohn s Disease
In 1932, Crohn, Ginzburg and Oppenheimer accurately described, from resected specimens, the homogeneous picture of a sub-acute or chronic...
The Role of Mucosal Healing in the Treatment of Crohn s Disease and Ulcerative Colitis
More important, ulcerations are at the origin of complications as fistula tracts, bacterial translocation leading to abscess formation and/or toxic...
The Role of Serological Testing in the Diagnosis and Management of Patients with Inflammatory Bowel Disease
Serology TestingSeveral experimental animal models of IBD have led to the theory that the pathogenesis of IBD is the result of an aberrant immune...
Tumor Necrosis Factor-α Inhibitor Failure
Disease severity can be classified into mild, moderate, or severe based on clinical signs and symptoms, including the amount of abdominal pain, the...
Update in Medical Therapy of Ulcerative Colitis
Mild to Moderate Ulcerative Colitis 5-aminosalicylic acid (5-ASA) has been extensively evaluated and is considered the first-line therapy for mild to...
Wireless Capsule Endoscopy A Diagnostic Tool for Early Crohn s Disease
Reference Section a report by Sandra L Jungles, BSN, RN Member, Society of Gastroenterology Nurses and Associates...
